Stroke and anti-VEGF therapy

Ophthalmology

Volumn 118, Issue 10, 2011, Pages

  Ueta, Takashi ^a   Mori, Harushi ^a   Kunimatsu, Akira ^a   Yamaguchi, Takuhiro ^a   Tamaki, Yasuhiro ^a   Yanagi, Yasuo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC THERAPY; ASYMPTOMATIC DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN RADIOGRAPHY; CEREBELLUM INFARCTION; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EXUDATIVE MACULAR DEGENERATION; HEART INFARCTION; HUMAN; LETTER; MYOPIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA SURGERY; STROKE; SUBRETINAL NEOVASCULARIZATION;

EID: 80053583300     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.06.001     Document Type: Letter

References (4)

1. T. Ueta, Y. Yanagi, Y. Tamaki, and T. Yamaguchi Cerebrovascular accidents in ranibizumab Ophthalmology 116 2009 362
2. D.S. Boyer, J.S. Heier, and D.M. Brown A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
3. Genentech Safety Update on Lucentis http://www.fda.gov/medwatch/safety/ 2007/Lucentis-DHCP-01-24-2007.pdf 2007 Accessed: March 8, 2011
4. T. Ueta, Y. Yanagi, Y. Tamaki, and T. Yamaguchi Ranibizumab and stroke Ophthalmology 117 2010 1860 author reply 1860-1